The diagnostic value of CD1d expression in a large cohort of patients with B-cell chronic lymphoproliferative disorders

American Journal of Clinical Pathology

Volumn 136, Issue 3, 2011, Pages 400-408

  Kotsianidis, Ioannis ^a   Nakou, Evangelia ^a   Spanoudakis, Emmanouil ^a   Bouchliou, Irene ^a   Moustakidis, Eleytherios ^a   Miltiades, Paraskevi ^a   Vadikolia, Chrisa M ^a   Szydlo, Richard ^b   Karadimitris, Anastasios ^b   Tsatalas, Costas ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

B cell chronic lymphoproliferative disorders; CD1d; Chronic lymphocytic leukemia; CLL; Immunophenotyping

Indexed keywords

CD1D ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; FLOW CYTOMETRY; HAIRY CELL LEUKEMIA; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; LYMPHOPLASMACYTIC LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; SPLENIC MARGINAL ZONE LYMPHOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD1D; B-LYMPHOCYTES; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY;

EID: 80052676080     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP2F2DOXOTXHZA     Document Type: Article

References (43)

1. Catovsky D. Chronic lymphoproliferative disorders. Curr Opin Oncol. 1995;7:3-11.
2. Montserrat E. Chronic lymphoproliferative disorders. Curr Opin Oncol. 1997;9:34-41. (Pubitemid 27142550)
3. Craig FE, Foon KA. Flow cytometric immunophenotyping for hematologic neoplasms. Blood. 2008;111:3941-3967.
4. Costa ES, Pedreira CE, Barrena S, et al. Automated pattern-guided principal component analysis vs expert-based immunophenotypic classification of B-cell chronic lymphoproliferative disorders: a step forward in the standardization of clinical immunophenotyping. Leukemia. 2010;24:1927-1933.
5. Kaleem Z. Flow cytometric analysis of lymphomas: current status and usefulness. Arch Pathol Lab Med. 2006;130:1850-1858. (Pubitemid 44906966)
6. Ho AK, Hill S, Preobrazhensky SN, et al. Small B-cell neoplasms with typical mantle cell lymphoma immunophenotypes often include chronic lymphocytic leukemias. Am J Clin Pathol. 2009;131:27-32.
7. Fu K, Weisenburger DD, Greiner TC, et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood. 2005;106:4315-4321. (Pubitemid 41775942)
8. Dronca RS, Jevremovic D, Hanson CA, et al. CD5-positive chronic B-cell lymphoproliferative disorders: diagnosis and prognosis of a heterogeneous disease entity. Cytometry B Clin Cytom. 2010;78(suppl 1):S35-S41.
9. Ugo V, Leporrier N, Salaun V, et al. Deciphering leukemic B-cell chronic lymphoproliferative disorders. Leuk Lymphoma. 2006;47:2088-2095. (Pubitemid 44650084)
10. Kost CB, Holden JT, Mann KP. Marginal zone B-cell lymphoma: a retrospective immunophenotypic analysis. Cytometry B Clin Cytom. 2008;74:282-286.
11. Konoplev S, Medeiros LJ, Bueso-Ramos CE, et al. Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Am J Clin Pathol. 2005;124:414-420. (Pubitemid 41232928)
12. Porcelli SA, Modlin RL. The CD1 system: antigen-presenting molecules for T cell recognition of lipids and glycolipids. Annu Rev Immunol. 1999;17:297-329. (Pubitemid 29241127)
13. Exley M, Garcia J, Wilson SB, et al. CD1d structure and regulation on human thymocytes, peripheral blood T cells, B cells and monocytes. Immunology. 2000;100:37-47. (Pubitemid 30242880)
14. Kotsianidis I, Silk JD, Spanoudakis E, et al. Regulation of hematopoiesis in vitro and in vivo by invariant NKT cells. Blood. 2006;107:3138-3144.
15. Metelitsa LS, Weinberg KI, Emanuel PD, et al. Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells. Leukemia. 2003;17:1068-1077. (Pubitemid 36722236)
16. Fais F, Tenca C, Cimino G, et al. CD1d expression on B-precursor acute lymphoblastic leukemia subsets with poor prognosis. Leukemia. 2005;19:551-556. (Pubitemid 40521159)
17. Nebozhyn M, Loboda A, Kari L, et al. Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy. Blood. 2006;107:3189-3196.
18. Spanoudakis E, Hu M, Naresh K, et al. Regulation of multiple myeloma survival and progression by CD1d. Blood. 2009;113:2498-2507.
19. Zheng Z, Venkatapathy S, Rao G, et al. Expression profiling of B cell chronic lymphocytic leukemia suggests deficient CD1-mediated immunity, polarized cytokine response, altered adhesion and increased intracellular protein transport and processing of leukemic cells. Leukemia. 2002;16:2429-2437. (Pubitemid 36054378)
20. Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003;3:185-197. (Pubitemid 37443390)
21. Fais F, Morabito F, Stelitano C, et al. CD1d is expressed on B-chronic lymphocytic leukemia cells and mediates alpha-galactosylceramide presentation to natural killer T lymphocytes. Int J Cancer. 2004;109:402-411. (Pubitemid 38252769)
22. Xu C, De Vries R, Visser L, et al. Expression of CD1d and presence of invariant NKT cells in classical Hodgkin lymphoma. Am J Hematol. 2009;85:539-541.
23. Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program. 2009:523-531.
24. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840-1847. (Pubitemid 29430399)
25. Gattei V, Bulian P, Del Principe MI, et al. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood. 2008;111:865-873.
26. Van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17:2257-2317. (Pubitemid 38072572)
27. Matutes E, Carrara P, Coignet L, et al. FISH analysis for BCL-1 rearrangements and trisomy 12 helps the diagnosis of atypical B cell leukaemias. Leukemia. 1999;13:1721-1726. (Pubitemid 29535253)
28. Quijano S, Lopez A, Rasillo A, et al. Impact of trisomy 12, del(13q), del(17p), and del(11q) on the immunophenotype, DNA ploidy status, and proliferative rate of leukemic B-cells in chronic lymphocytic leukemia. Cytometry B Clin Cytom. 2008;74:139-149. (Pubitemid 351656293)
29. Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia. 1994;8:1640-1645. (Pubitemid 24323778)
30. Morice WG, Kurtin PJ, Hodnefield JM, et al. Predictive value of blood and bone marrow flow cytometry in B-cell lymphoma classification: comparative analysis of flow cytometry and tissue biopsy in 252 patients. Mayo Clin Proc. 2008;83:776-785. (Pubitemid 351948691)
31. Gong JZ, Lagoo AS, Peters D, et al. Value of CD23 determination by flow cytometry in differentiating mantle cell lymphoma from chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Clin Pathol. 2001;116:893-897. (Pubitemid 33108161)
32. Tefferi A, Bartholmai BJ, Witzig TE, et al. Heterogeneity and clinical relevance of the intensity of CD20 and immunoglobulin light-chain expression in B-cell chron ic lymphocytic leukemia. Am J Clin Pathol. 1996;106:457-461. (Pubitemid 26332994)
33. Asplund SL, McKenna RW, Doolittle JE, et al. CD5-positive B-cell neoplasms of indeterminate immunophenotype: a clinicopathologic analysis of 26 cases. Appl Immunohistochem Mol Morphol. 2005;13:311-317. (Pubitemid 41697392)
34. Pillai S, Cariappa A, Moran ST. Marginal zone B cells. Annu Rev Immunol. 2005;23:161-196. (Pubitemid 40563168)
35. Chen QY, Zhang T, Pincus SH, et al. Human CD1D gene expression is regulated by LEF-1 through distal promoter regulatory elements. J Immunol. 2010;184:5047-5054.
36. Howe D, Bromidge T. Variation of LEF-1 mRNA expression in low-grade B-cell non-Hodgkin's lymphoma. Leuk Res. 2006;30:29-32. (Pubitemid 41654701)
37. Ocio EM, Hernandez JM, Mateo G, et al. Immunophenotypic and cytogenetic comparison of Waldenström's macroglobulinemia with splenic marginal zone lymphoma. Clin Lymphoma. 2005;5:241-245. (Pubitemid 40614234)
38. Sanchez ML, Almeida J, Vidriales B, et al. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation. Leukemia. 2002;16:1460-1469.
39. Sah SP, Matutes E, Wotherspoon AC, et al. A comparison of flow cytometry, bone marrow biopsy, and bone marrow aspirates in the detection of lymphoid infiltration in B cell disorders. J Clin Pathol. 2003;56:129-132. (Pubitemid 36177256)
40. Del Giudice I, Matutes E, Morilla R, et al. The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytes. Haematologica. 2004;89:303-308. (Pubitemid 38788414)
41. Dong HY, Weisberger J, Liu Z, et al. Immunophenotypic analysis of CD103+ B-lymphoproliferative disorders: hairy cell leukemia and its mimics. Am J Clin Pathol. 2009;131:586-595.
42. Hockley SL, Giannouli S, Morilla A, et al. Insight into the molecular pathogenesis of hairy cell leukaemia, hairy cell leukaemia variant and splenic marginal zone lymphoma, provided by the analysis of their IGH rearrangements and somatic hypermutation patterns. Br J Haematol. 2010;148:666-669.
43. Weill JC, Weller S, Reynaud CA. Human marginal zone B cells. Annu Rev Immunol. 2009;27:267-285.